GlassScriptPhysician profile
Ernest Terrill Smith
NPI 1356519706
$7,059.66
in general payments reported to CMS, 2019-2025
29 companies · $4,318 in 2025
The $4,318 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $76.17 · 2024: $2,665 · 2025: $4,318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,755 · Education: $286 · Travel and Lodging: $17.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,755.32 |
| Education | $286.49 |
| Travel and Lodging | $17.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,932.96 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $594.31 | 2024-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Alkermes, INC. | $589.18 | 2024-2025 | Aristada, Lybalvi, Vivitrol |
| Forte Bio-Pharma LLC | $548.02 | 2024-2025 | Prolate, Nalocet, Tanlor |
| Vanda Pharmaceuticals INC. | $483.78 | 2024-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $463.10 | 2024-2025 | Caplyta |
| Lilly USA, LLC | $460.03 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $448.16 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Axsome Therapeutics, INC. | $349.71 | 2024-2025 | Auvelity, Symbravo |
| Otsuka America Pharmaceutical, INC. | $184.16 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $167.21 | 2024-2025 | Ingrezza |
| Pfizer INC. | $130.98 | 2024-2025 | |
| Tris Pharma INC | $120.71 | 2024 | Dyanavel Xr |
| Corcept Therapeutics | $99.05 | 2025 | Korlym |
| Amgen INC. | $62.09 | 2024-2025 | Repatha, Otezla, Otezla |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $60.99 | 2024 | Loreev Xr |
| Collegium Pharmaceutical, INC. | $54.86 | 2024-2025 | Belbuca |
| E.R. Squibb & Sons, L.L.C. | $44.73 | 2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $43.46 | 2025 | Qelbree |
| Lundbeck LLC | $41.62 | 2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $35.92 | 2024-2025 | Airsupra |
| Abbott Laboratories | $21.96 | 2025 | Freestyle Libre 3 |
| Ardelyx, INC. | $20.12 | 2025 | Ibsrela |
| Hologic Sales and Service, LLC | $19.70 | 2025 | Aptima |
| Eisai INC. | $19.14 | 2024 | |
| Neos Therapeutics, LP | $17.07 | 2024 | Adzenys Xr-Odt |
| Virtus Pharmaceuticals LLC | $16.85 | 2024 | Levorphanol Tartrate |
| Ironwood Pharmaceuticals, INC | $14.95 | 2024 | |
| Phathom Pharmaceuticals, INC. | $14.84 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ernest Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.